Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Reuter

Showing results (11-20 of 176) with videos related to

Pageof 18
Sort By:
Current Neurology and Neuroscience Reports|February 14, 2003
Pathophysiology of headacheMargarita Sánchez del Río, Uwe Reuter
Current Opinion in Neurology|May 29, 2004
Migraine aura: new information on underlying mechanismsMargarita Sánchez-del-Rio, Uwe Reuter
Expert Opinion on Biological Therapy|September 26, 2019
Monoclonal antibodies for the prevention of migraineBianca Raffaelli, Lars Neeb, Uwe Reuter
Current Pain and Headache Reports|April 7, 2018
CGRP Monoclonal Antibodies for the Preventative Treatment of MigraineHeike Israel, Lars Neeb, Uwe Reuter
Integrative Cancer Therapies|May 22, 2016
Coley's Lessons Remembered: Augmenting Mistletoe TherapyMaurice Orange, Uwe Reuter, Uwe Hobohm
Expert Opinion on Pharmacotherapy|June 14, 2022
Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraineMira Fitzek, Bianca Raffaelli, Uwe Reuter
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 1, 2010
5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?Lars Neeb, Jannis Meents, Uwe Reuter
Therapeutic Advances in Neurological Disorders|January 14, 2015
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraineUwe Reuter, Heike Israel, Lars Neeb
Expert Opinion on Biological Therapy|January 20, 2025
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biologyRobert Fleischmann, Sebastian Strauß, Uwe Reuter
Trends in Molecular Medicine|March 30, 2010
TRPV1 in migraine pathophysiologyJannis E Meents, Lars Neeb, Uwe Reuter
Pageof 18

Showing results (11-20 of 176) with videos related to

Sort By:
Pageof 18
Current Neurology and Neuroscience Reports|February 14, 2003
Pathophysiology of headacheMargarita Sánchez del Río, Uwe Reuter
Current Opinion in Neurology|May 29, 2004
Migraine aura: new information on underlying mechanismsMargarita Sánchez-del-Rio, Uwe Reuter
Expert Opinion on Biological Therapy|September 26, 2019
Monoclonal antibodies for the prevention of migraineBianca Raffaelli, Lars Neeb, Uwe Reuter
Current Pain and Headache Reports|April 7, 2018
CGRP Monoclonal Antibodies for the Preventative Treatment of MigraineHeike Israel, Lars Neeb, Uwe Reuter
Integrative Cancer Therapies|May 22, 2016
Coley's Lessons Remembered: Augmenting Mistletoe TherapyMaurice Orange, Uwe Reuter, Uwe Hobohm
Expert Opinion on Pharmacotherapy|June 14, 2022
Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraineMira Fitzek, Bianca Raffaelli, Uwe Reuter
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 1, 2010
5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?Lars Neeb, Jannis Meents, Uwe Reuter
Therapeutic Advances in Neurological Disorders|January 14, 2015
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraineUwe Reuter, Heike Israel, Lars Neeb
Expert Opinion on Biological Therapy|January 20, 2025
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biologyRobert Fleischmann, Sebastian Strauß, Uwe Reuter
Trends in Molecular Medicine|March 30, 2010
TRPV1 in migraine pathophysiologyJannis E Meents, Lars Neeb, Uwe Reuter
Pageof 18